Edition:
United States

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

56.23CNY
11:17pm EDT
Change (% chg)

¥-0.16 (-0.28%)
Prev Close
¥56.39
Open
¥56.37
Day's High
¥57.06
Day's Low
¥56.12
Volume
2,665,142
Avg. Vol
5,277,108
52-wk High
¥57.06
52-wk Low
¥36.98

Latest Key Developments (Source: Significant Developments)

Jiangsu Hengrui Medicine's Q1 net profit up 18.6 pct y/y
Thursday, 20 Apr 2017 04:06am EDT 

April 20 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says Q1 net profit up 18.6 pct y/y at 811.8 million yuan ($117.92 million).  Full Article

Jiangsu Hengrui Medicine receives new drug license
Thursday, 16 Mar 2017 05:00am EDT 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> : Says the co received new drug license for Caspofungin Acetate for Injection, getting approval to sell it in UK and Germany .The new drug is used for virulence Aspergillus treatment.  Full Article

Jiangsu Hengrui Medicine announces FY 2016 dividend payment
Monday, 13 Mar 2017 10:55am EDT 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> : Says it plans to use undistributed profits to pay a cash dividend of 1.35 yuan (pre-tax) per 10 shares to shareholders for FY 2016 .To distribute two new share for every 10 shares as stock dividends.  Full Article

Jiangsu Hengrui Medicine's 2016 net profit up 19.2 pct
Friday, 10 Mar 2017 06:31am EST 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> :Says its 2016 net profit up 19.2 percent y/y at 2.6 billion yuan ($376.08 million).  Full Article

Jiangsu Hengrui Medicine and unit get approval for drug clinical trial
Friday, 10 Mar 2017 03:29am EST 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> : Says the co and its unit received approval from China Food and Drug Administration to start new drug SHR-1309 injection clinical trial . SHR-1309 injection is used for HER2 positive metastatic breast cancer treatment .The co and its unit will be able to sell SHR-1309 injection after getting approval from China Food and Drug Administration.  Full Article

Jiangsu Hengrui Medicine passes FDA approval
Tuesday, 7 Feb 2017 09:47pm EST 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> : Says co received approval for its Cisatracurium Besylate injection from U.S Food and Drug Administration .The company will be able to manufacture and sell its injection in the United States after receiving the FDA approval.  Full Article

Oncolys BioPharma signs exclusive license agreement with Jiangsu Hengrui Medicine on OBP-301 in China
Wednesday, 30 Nov 2016 04:16am EST 

Oncolys BioPharma Inc <4588.T> : Says co enters into exclusive license agreement with Jiangsu Hengrui Medicine Co Ltd for OBP-301, valid in China mainland, Hong Kong and Macao .Previous plan was disclosed on May 20.  Full Article

Jiangsu Hengrui Medicine and unit commence phase I clinical trial for SHR-1314
Thursday, 17 Nov 2016 03:45am EST 

Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says the co and its unit commenced phase I clinical trial for injection SHR-1314.  Full Article

Jiangsu Hengrui Medicine's H1 net profit up 24 pct y/y
Monday, 29 Aug 2016 07:16am EDT 

Jiangsu Hengrui Medicine Co Ltd <600276.SS> :Says H1 net profit up 23.85 percent y/y at 1.3 billion yuan ($194.66 million).  Full Article

Jiangsu Hengrui Medicine and unit receive approval for drug clinic trial
Tuesday, 5 Jul 2016 01:47am EDT 

Jiangsu Hengrui Medicine <600276.SS> Co., Ltd.:Says the co and unit get China Food and Drug Administration's approval for its SHR-1314 injection which will be mainly used for the treatment of psoriasis.  Full Article

More From Around the Web